Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4

NCT01686789 is registered in ClinicalTrials.gov with King Abdulaziz Medical City as lead sponsor.

NCT NCT01686789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01686789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4
Lead sponsor
King Abdulaziz Medical City
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2011
Completion date
August 31, 2015
Enrollment
181 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c virus